FDA outlines risk-based approach to monitoring clinical trials
FDA issues guidance on risk-based clinical trial monitoring: The FDA released a final guidance explaining risk-based strategies that can be used by drug and device developers to monitor clinical trials of biological products, drugs, medical devices and combination products. The Agency said the document, which comes in question-and-answer format, “contains recommendations on planning a monitoring approach, developing the content of a monitoring plan, and addressing and communicating monitoring results.”